Apria Healthcare Group Inc. Announces First Quarter 2013 Financial Results


LAKE FOREST, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- Apria Healthcare Group Inc. ("Apria" or the "Company"), a quality, cost-efficient provider of home healthcare products and services in the United States, today announced its financial results for the quarter ended March 31, 2013.

2013 First Quarter Highlights

Net revenues in the three months ended March 31, 2013 were $614.7 million, compared to $595.7 million in the three months ended March 31, 2012, an increase of $19.0 million or 3.2%. Revenue for the three months ended March 31, 2013 increased primarily due to increased volume in the home infusion therapy segment partially offset by decreased volume in the home respiratory and home medical equipment segment.

Adjusted EBITDA before projected cost savings and synergies1 for the three months ended March 31, 2013 was $71.1 million compared to $58.7 million in the three months ended March 31, 2012, an increase of 21.1%.

Free cash flow for the three months ended March 31, 2013 was $1.5 million compared to $(15.4) million in the three months ended March 31, 2012, an increase of $16.9 million.

Net loss for the three months ended March 31, 2013 was $1.9 million.

EBITDA for the three months ended March 31, 2013 was $58.6 million.

Certain Credit Statistics

Our net leverage ratio, defined as the ratio of net debt to Adjusted EBITDA, was 3.5x at March 31, 2013.

Conference Call

As previously announced, Apria will hold a conference call to discuss its first quarter 2013 results on May 1, 2013 at 1:00 p.m. (Eastern Daylight Time). The conference call can be accessed over the phone by dialing 888-536-6116 or, for international callers, 706-679-8204 or through the Investor Relations page of the Company's website at www.apria.com. The passcode for the call is Apria.

A replay of the conference call will be available two hours after the call and can be accessed by dialing 855-859-2056 or, for international callers, 404-537-3406 or through the Investor Relations page of the Company's website. The passcode for the replay is 55309752. The replay will be available until May 15, 2013.

A financial results presentation will be made available immediately prior to the call on the Investor Relations page of the Company's website at www.apria.com.

1 This press release includes several metrics, including EBITDA, Adjusted EBITDA and Adjusted EBITDA before projected cost savings and synergies that are not calculated in accordance with Generally Accepted Accounting Principles ("GAAP"). See "Definition of Terms and Reconciliation of Non-GAAP Financial Measures" section at the end of this press release for the definitions of EBITDA, Adjusted EBITDA and Adjusted EBITDA before projected cost savings and synergies and their reconciliation to net income (loss).

Forward Looking Statements

Statements contained herein that are not historical facts and that reflect the current view of Apria's management about future events and financial performance are hereby identified as "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some of these statements can be identified by terms and phrases such as "anticipate," "believe," "intend," "estimate," "expect," "continue," "could," "should," "may," "plan," "project," "predict" and similar expressions. The Company cautions that such "forward looking statements," including without limitation, those relating to the Company's future business prospects, revenue, working capital, professional liability expense, liquidity, capital needs, interest costs and income, wherever they occur in this or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company's senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward looking statements." Factors that could cause our actual results to differ materially from those expressed or implied in such forward looking statements include but are not limited to current or future government regulation of the healthcare industry, exposure to professional liability lawsuits and governmental agency investigations, the adequacy of insurance coverage and insurance reserves, control issues in the Company's internal controls and procedures, as well as other factors detailed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition" in the Company's filings with the Securities and Exchange Commission. The Company's "forward looking statements" speak only as of the date hereof and the Company disclaims any intent or obligation to update "forward looking statements" herein to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

About Apria Healthcare Group Inc.

Apria provides home respiratory therapy, home infusion therapy and home medical equipment services through approximately 520 locations in the United States. With $2.4 billion in annual revenues, it is one of the nation's leading home healthcare companies. For more information, visit www.apria.com or www.coramhc.com.

 
 
Apria Healthcare Group Inc.
Condensed Consolidated Balance Sheets
 
  March 31,  2013   December 31, 
2012
  
     
  (in thousands, except share data)
ASSETS  
CURRENT ASSETS    
Cash and cash equivalents $ 15,523 $ 27,080
Accounts receivable, less allowance for doubtful accounts of $60,447 and $53,017 at March 31, 2013 and December 31, 2012, respectively  349,877  344,421
Inventories  71,200  68,075
Deferred expenses  3,701  3,798
Prepaid expenses and other current assets  23,190  16,890
     
TOTAL CURRENT ASSETS  463,491  460,264
PATIENT SERVICE EQUIPMENT, less accumulated depreciation of $186,885 and $185,744 at March 31, 2013 and December 31, 2012, respectively  190,482  186,460
PROPERTY, EQUIPMENT AND IMPROVEMENTS, NET  74,498  76,823
GOODWILL  258,725  258,725
INTANGIBLE ASSETS, NET  133,595  133,781
DEFERRED DEBT ISSUANCE COSTS, NET  26,373  30,207
OTHER ASSETS  28,172  26,448
     
TOTAL ASSETS $ 1,175,336 $ 1,172,708
     
LIABILITIES AND STOCKHOLDERS' DEFICIT    
CURRENT LIABILITIES    
Accounts payable $ 147,239 $ 157,530
Accrued payroll and related taxes and benefits  70,811  70,547
Deferred income taxes  2,730  986
Other accrued liabilities  101,089  74,464
Deferred revenue  27,246  27,785
Current portion of long-term debt  12,136  25,195
     
TOTAL CURRENT LIABILITIES  361,251  356,507
LONG-TERM DEBT, net of current portion  1,017,500  1,017,515
DEFERRED INCOME TAXES  67,539  68,907
INCOME TAXES PAYABLE AND OTHER NON-CURRENT LIABILITIES  61,042  61,203
     
TOTAL LIABILITIES  1,507,332  1,504,132
COMMITMENTS AND CONTINGENCIES    
STOCKHOLDERS' DEFICIT    
Common stock, $0.01 par value: 1,000 shares authorized; 100 shares issued at March 31, 2013 and December 31, 2012  —   —
Additional paid-in capital  696,532  695,211
Accumulated deficit  (1,028,528)  (1,026,635)
TOTAL STOCKHOLDERS' DEFICIT  (331,996)  (331,424)
  $ 1,175,336 $ 1,172,708
     
 
Apria Healthcare Group Inc.
Condensed Consolidated Statements of Operations
 
 
  Three Months Ended March 31,  
  2013   2012  
  (Unaudited)
  (in thousands)
Net revenues:    
Fee for service arrangements $ 569,520 $ 551,616
Capitation arrangements  45,235  44,097
     
TOTAL NET REVENUES  614,755  595,713
     
Costs and expenses:    
Cost of net revenues:    
Product and supply costs  220,754  207,412
Patient service equipment depreciation  19,458  20,696
Home respiratory therapy services  5,649  7,289
Nursing services  9,953  11,223
Other  4,408  5,046
     
TOTAL COST OF NET REVENUES  260,222  251,666
Provision for doubtful accounts  23,135  11,858
Selling, distribution and administrative  299,149  317,422
Amortization of intangible assets  186  661
     
TOTAL COSTS AND EXPENSES  582,692  581,607
     
OPERATING INCOME  32,063  14,106
Interest expense  34,212  33,517
Interest income and other  (510)  (702)
     
LOSS BEFORE TAXES  (1,639)  (18,709)
Income tax expense  254  898
     
NET LOSS $ (1,893) $ (19,607)
     
 
Apria Healthcare Group Inc.
Condensed Consolidated Statements of Cash Flows
 
 
  Three Months Ended March 31,
  2013 2012
    (As Restated)
  (Unaudited)
  (in thousands)
OPERATING ACTIVITIES    
Net loss $ (1,893) $ (19,607)
Items included in net loss not requiring cash:    
Provision for doubtful accounts  23,135  11,858
Depreciation  26,361  28,705
Amortization of intangible assets  186  661
Amortization of deferred debt issuance costs  3,834  3,451
Deferred income taxes  375  137
Profit interest compensation  1,321  739
Gain on sale of patient service equipment and other  (6,086)  (5,915)
Changes in operating assets and liabilities, exclusive of effects of acquisitions:    
Accounts receivable  (28,592)  (37,125)
Inventories  (3,125)  (6,344)
Prepaid expenses and other assets  (8,026)  (2,575)
Accounts payable  (6,360)  15,062
Accrued payroll and related taxes and benefits  265  2,462
Income taxes payable  99  260
Deferred revenue, net of related expenses  (442)  (1,062)
Accrued expenses  26,367  27,149
     
NET CASH PROVIDED BY OPERATING ACTIVITIES  27,419  17,856
     
INVESTING ACTIVITIES    
Purchases of patient service equipment and property, equipment and improvements, exclusive of effects of acquisitions  (36,909)  (44,783)
Proceeds from sale of patient service equipment and other  11,007  11,525
Cash paid for acquisitions  —   (94)
     
NET CASH USED IN INVESTING ACTIVITIES  (25,902)  (33,352)
     
FINANCING ACTIVITIES    
Proceeds from ABL Facility  146,000  67,000
Payments on ABL Facility (159,000)  (57,000)
Payments on other long-term debt  (74)  (86)
     
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES  (13,074)  9,914
     
NET DECREASE IN CASH AND CASH EQUIVALENTS  (11,557)  (5,582)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  27,080  29,096
     
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 15,523 $ 23,514
     
 
 
Apria Healthcare Group Inc.
1st Quarter 2013 Financial Summary
 
 
  Three Months Ended March 31,      
($ in millions)
2013

2012
$ Variance
Fav/(Unfav)
% Variance
Fav/(Unfav)
Net Revenue $ 614.7 $ 595.7 $ 19.0  3.2%
         
Gross Profit  354.5  344.0  10.5  3.1%
% Margin  57.7%  57.8%    
         
Provision for Doubtful Accounts  23.1  11.9  (11.2)  (94.1)%
% of Net Revenue  3.8%  2.0%    
         
Selling, Distribution and Administrative  299.1  317.4  18.3  5.8%
% of Net Revenue  48.7%  53.3%    
         
Net Loss  (1.9)  (19.6)  17.7  90.3%
         
EBITDA  58.6  43.5  15.1  (34.7)%
         
Adjusted EBITDA Before Projected Cost Savings and Synergies  71.1  58.7  12.4  21.1%
% of Net Revenue  11.6%  9.9%      
 
 
Segment Revenue Performance
 
($ in millions) Three Months Ended March 31, $ Variance % Variance
  2013 2012 Fav/(Unfav) Fav/(Unfav)
Home Respiratory Therapy and Home Medical Equipment $ 298.5 $ 300.9 $ (2.4)  (0.8)%
Home Infusion Therapy  316.2  294.8  21.4  7.3%
         
Total Net Revenue $ 614.7 $ 595.7 $ 19.0  3.2%
         

Cash and Cash Equivalents, Capitalization & Certain Credit Statistics

The following table indicates the cash and cash equivalents, capitalization and certain credit statistics as of March 31, 2013:

   
($ in millions) March 31,
2013  
Cash and Cash Equivalents $ 15.5
   
Debt  
Asset Based Revolving Credit Facility  12.0
Series A-1 Notes  700.0
Series A-2 Notes  317.5
Capital Leases & Other  0.1
   
Total Debt $ 1,029.6
Shareholders' Deficit  (332.0)
   
Total Capitalization $ 697.6
   
   
Net Leverage Ratio Calculations  
Net Debt1 $ 1,014.1
   
Adjusted EBITDA2 $ 287.1
Net Leverage Ratio3  3.5x
 
1 Net debt is defined as total debt less cash and cash equivalents. This amount does not reflect outstanding letters of credit. 
2 For the twelve months ended March 31, 2013.
3 Net leverage ratio is defined as the ratio of net debt to Adjusted EBITDA. The net leverage ratio calculated using Adjusted EBITDA before projected cost savings and synergies was 3.6x. 

Definition of Terms and Reconciliation of Non-GAAP Financial Measures

This press release includes several metrics which are not calculated in accordance with GAAP, including EBITDA, Adjusted EBITDA, Adjusted EBITDA before projected cost savings and synergies and Free Cash Flow. EBITDA, Adjusted EBITDA, Adjusted EBITDA before projected cost savings and synergies and Free Cash Flow are not recognized terms under GAAP and do not purport to be an alternative to net income as a measure of operating performance or to cash flows from operating activities as a measure of liquidity. Additionally, these measures are not intended to be measures of Free Cash Flow available for management's discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. Our presentation of EBITDA, Adjusted EBITDA, Adjusted EBITDA before projected cost savings and synergies and Free Cash Flow may not be comparable to other similarly titled measures of other companies. We believe that such measures provide useful information about our financial condition and covenant compliance under the indenture governing our Series A-1 Notes and Series A-2 Notes and in our ABL Facility to investors and we compensate for the limitations of using non-GAAP financial measures by presenting them together with GAAP results to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

EBITDA is defined as net income (loss) before interest expense, net, income tax expense and depreciation and amortization.

Adjusted EBITDA is defined as net income (loss) before interest expense, net, income tax expense and depreciation and amortization, further adjusted to exclude certain non-cash items, costs incurred related to initiatives, other adjustment items and projected cost savings and synergies permitted in calculating covenant compliance under the indenture governing our Series A-1 Notes and Series A-2 Notes and the credit agreement governing our ABL Facility.

Adjusted EBITDA before projected cost savings and synergies is defined as Adjusted EBITDA less the projected cost savings and synergies that we expect to realize in connection with cost savings, restructuring and other similar initiatives.

Free Cash Flow is defined as cash provided by operating activities less purchases of patient service equipment and property, equipment and improvements, net of proceeds from the sale of patient service equipment and other, exclusive of effects of acquisitions.

The following tables provide reconciliation of EBITDA, Adjusted EBITDA, Adjusted EBITDA before projected cost savings and synergies and Free Cash Flow for the periods presented to the respective most closely comparable financial measures calculated in accordance with GAAP.

Reconciliation of EBITDA, Adjusted EBITDA and Adjusted EBITDA before projected cost savings and synergies

  Three Months Ended
 March 31, 
LTM
 March 31,
(in millions)  2013   2012   2013 
       
Net Loss   $ (1.9)   $ (19.6)   $ (242.7)
Interest expense, net   33.7  32.8   134.4
Income tax expense (benefit)  0.3  0.9  (131.5)
Depreciation and amortization   26.5   29.4   111.1
       
EBITDA   58.6  43.5   (128.7)
Non-cash impairment of goodwill, intangible and long-lived assets   —   —  350.0
Non-cash items   6.2   6.4  22.8
       
Costs incurred related to Initiatives and non-recurring items   4.5   7.1   30.7
       
Other adjustments   1.8   1.7   7.0
       
Adjusted EBITDA Before Projected Cost Savings and Synergies $ 71.1 $ 58.7   281.8
Projected cost savings and synergies      5.3
Adjusted EBITDA     $ 287.1

Reconciliation of Free Cash Flow

(in millions) Three Months Ended
March 31, 2013  
Net Loss  $ (1.9) 
Non-cash items  49.1
Change in operating assets and liabilities   (19.8)
Net cash provided by operating activities  27.4
Purchases of patient service equipment, property, equipment and improvements  (36.9)
Proceeds from sale of patient service equipment and other   11.0
Free Cash Flow  $ 1.5

            

Contact Data